Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) Basal 18F-FDG PET/CT in follicular lymphoma: A comparison of metabolic and clini...
Journal Information
Vol. 35. Issue 5.
Pages 298-305 (September - October 2016)
Share
Share
Download PDF
More article options
Visits
7
Vol. 35. Issue 5.
Pages 298-305 (September - October 2016)
Original article
Basal 18F-FDG PET/CT in follicular lymphoma: A comparison of metabolic and clinical variables in the prognostic assessment
Valor de la 18F-FDG PET/TC basal en el linfoma folicular: comparación de las variables metabólicas y clínicas en la valoración pronóstica
Visits
7
G.A. Jiménez Londoñoa,
Corresponding author
gjimenez91@yahoo.com

Corresponding author.
, A.M. García Vicentea, V.M. Poblete Garcíaa, M. Amo-Salasb, C. Calle Primoc, Á. Ibañez Garcíad, B. Martínez Sanchísa, J.F. López-Fidalgob, F. Solano Ramose, A. Martínez Hellínd, M. Díaz Morfaf, Á. Soriano Castrejóna
a Department of Nuclear Medicine, Hospital General Universitario de Ciudad Real, Spain
b Department of Mathematics, University of Castilla La Mancha, Ciudad Real, Spain
c Department of Hematology, Hospital General Universitario de Ciudad Real, Spain
d Department of Hematology, Complejo Hospitalario Universitario de Albacete, Spain
e Department of Hematology, Hospital Ntra. Sra. del Prado, Talavera de la Reina, Toledo, Spain
f Department of Hematology, Hospital Universitario de Guadalajara, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (4)
Table 1. Patient's disease characteristics.
Table 2. Relation of tumor SUVmax with disease characteristics.
Table 3. Relation of FLIPI risk with metabolic disease characteristics.
Table 4. Relation of metabolic disease characteristics with tumor burden.
Show moreShow less
Abstract
Aim

To analyze the relationship of clinical variables related to prognosis and tumor burden, with metabolic variables obtained in the staging 18F-FDG PET/CT, and their value in the prognosis in follicular lymphoma (FL).

Methods

82 patients with FL, a 18F-FDG PET/CT at diagnosis and a follow-up for a minimum of 12 months, were retrospectively enrolled in the present study. Clinical variables (Tumor grade, Follicular Lymphoma International Prognostic Index (FLIPI) and Tumor burden) were evaluated. Metabolic variables such as SUVmax in the highest hypermetabolic lesion, extralymphatic locations, number of involved lymph node locations, bone marrow (BM) involvement, PET stage and diameter of the biggest hypermetabolic lesion, were analyzed in order to establish a PET score and classify the studies in low, intermediate and high metabolic risk. Clinical and metabolic variables (included metabolic risk) were compared. The relation among all variables and disease-free survival (DFS) was studied.

Results

The 28% of patients had a high-grade tumor. The 30.5% had FLIPI risk low, 29.3% intermediate y 40.2% high. The 42.7% presented a high tumor burden.

The PET/CT was positive in 94% of patients. The tumor grade did not show significant relation with metabolic variable. FLIPI risk and tumor burden showed statistical relations with the SUV max and the PET score (p<0.008 and p=0.003 respectively). With respect to DFS, significant differences were detected for the PET stage and FLIPI risk (p=0.015 and p=0.047 respectively). FLIPI risk was the only significant predictor in Cox regression analysis, with a Hazard Ratio of 5.13 between high risk and low risk.

Conclusion

The present research highlights the significant relation between metabolic variables obtained with FDG PET/CT and clinical variables although their goal as an independent factor of prognosis was not demonstrated in the present work.

Keywords:
Follicular lymphoma
Staging
18F-FDG PET/CT
PET prognostic score
Prognosis
Metabolic risk
Resumen
Objetivo

Analizar la relación entre las variables clínicas relativas al pronóstico y la carga tumoral y las variables obtenidas en la 18F-FDG PET/TC de estadificación, así como su valor pronóstico para el linfoma folicular (LF).

Métodos

Se realizó un estudio retrospectivo de 82 pacientes con LF, 18F-FDG PET/TC en el momento del diagnóstico y seguimiento mínimo de 12 meses. Se evaluaron las variables clínicas (grado tumoral, Índice pronóstico internacional para el linfoma folicular (FLIPI) y carga tumoral). Se analizaron las variables metabólicas tales como SUVmax en las lesiones más hipermetabólicas, localizaciones extralinfáticas, número de localizaciones ganglionares afectas, afectación de la médula ósea, estadio PET y diámetro de la lesión hipermetabólica de mayor tamaño, a fin de establecer una puntuación PET y clasificar los estudios en riesgo bajo, medio y elevado. Se compararon las variables clínicas y metabólicas (incluyendo el riesgo metabólico) y se estudió la relación entre todas las variables y la supervivencia libre de enfermedad (SLE).

Resultados

El 28% de los pacientes tenían un tumor de alto grado. El 30,5% tenía un riesgo bajo de FLIPI, el 29,3% un grado intermedio y el 40,2% un riesgo elevado. El 42,7% presentó una elevada carga tumoral.

La PET/TC fue positiva en el 94% de los pacientes. El grado del tumor no reflejó una relación significativa con la variable metabólica. El riesgo de FLIPI y la carga tumoral guardaron relaciones estadísticas con SUVmax y la puntuación PET (p<0,008 y p=0,003, respectivamente). Con respecto a la SLE, se detectaron diferencias significativas para el estadio PET y el riesgo FLIPI (p=0,015 y p=0,047, respectivamente). El riesgo FLIPI fue el único factor predictivo significativo en el análisis de regresión, con un cociente de riesgo instantáneo (HR) de 5,13 entre alto y bajo riesgo.

Conclusión

La presente investigación resalta la considerable relación entre las variables metabólicas obtenidas con FDG PET/TC y las variables clínicas, aunque su objetivo como factor independiente de pronóstico no ha sido demostrado en el presente estudio.

Palabras clave:
Linfoma folicular
Estadificación
18F-FDG PET/TC
PET-TC Score
Pronóstico
Riesgo metabólico

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.remnie.2022.03.002
No mostrar más